Pharmacologic RNA splicing modulation: a novel mechanism to enhance neoantigen-directed anti-tumor immunity and immunotherapy response  

作　　者：Kerryn Elliott Jonas Nilsson Jimmy Van den Eynden 

机构地区：[1]Department of Medical Biochemistry and Cell Biology,Institute of Biomedicine,Sahlgrenska Academy at University of Gothenburg,Gothenburg,Sweden [2]Sahlgrenska Cancer Center,Department of Surgery,Institute of Clinical Sciences,University of Gothenburg and Sahlgrenska University Hospital,Gothenburg,Sweden [3]Harry Perkins Institute of Medical Research,University of Western Australia,Perth,WA,Australia [4]Department of Human Structure and Repair,Anatomy and Embryology Unit,Ghent University,Ghent,Belgium

出　　处：《Signal Transduction and Targeted Therapy》2021年第11期3167-3168,共2页信号转导与靶向治疗（英文）

基　　金：Open access funding provided by University of Gothenburg.

摘　　要：A recent study by Lu et al.1 suggests a novel approach to increasing responsiveness to immune checkpoint blockade (ICB) therapy. ICB is a promising form of cancer immunotherapy that aims to boost the anti-tumoral immune response. This response is primarily driven by the presentation of different types of antigens at the cancer cell membrane via the type I major histocompatibility complex (MHC I). Neoantigens are tumor-specific antigens that are small (mostly 9-mers) mutated peptides that generally result from somatic mutations. High tumor mutational burden, which results in the formation of many neoantigens, is currently one of the main biomarkers for ICB response prediction. Because ICB is only effective in a minority of patients, new therapeutic strategies are required to augment this response.

关 键 词：IMMUNITY IMMUNOTHERAPY mostly 

分 类 号：R730.51[医药卫生—肿瘤]